Diabetic Neuropathy - Pipeline Review, H1 2017

  • ID: 4284834
  • Report
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Apollo Endosurgery Inc
  • Celgene Corp
  • Grunenthal GmbH
  • KPI Therapeutics Inc
  • Neuralstem Inc
  • MORE
Diabetic Neuropathy - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Apollo Endosurgery Inc
  • Celgene Corp
  • Grunenthal GmbH
  • KPI Therapeutics Inc
  • Neuralstem Inc
  • MORE
Introduction

Diabetic Neuropathy - Overview

Diabetic Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Neuropathy - Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Angelini Group

Apollo Endosurgery Inc

Araim Pharmaceuticals Inc

Celgene Corp

Commence Bio Inc

Grunenthal GmbH

Kineta Inc

KPI Therapeutics Inc

Medifron DBT Co Ltd

Neuralstem Inc

NovaLead Pharma Pvt Ltd

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

ViroMed Co Ltd

Diabetic Neuropathy - Drug Profiles

A-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNV-222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cibinetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-2197944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-566 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-721 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTA-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Diabetic Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trazodone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XK-568b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Neuropathy - Dormant Projects

Diabetic Neuropathy - Discontinued Products

Diabetic Neuropathy - Product Development Milestones

Featured News & Press Releases

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Diabetic Neuropathy, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H1

Diabetic Neuropathy - Pipeline by Angelini Group, H1

Diabetic Neuropathy - Pipeline by Apollo Endosurgery Inc, H1

Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc, H1

Diabetic Neuropathy - Pipeline by Celgene Corp, H1

Diabetic Neuropathy - Pipeline by Commence Bio Inc, H1

Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H1

Diabetic Neuropathy - Pipeline by Kineta Inc, H1

Diabetic Neuropathy - Pipeline by KPI Therapeutics Inc, H1

Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H1

Diabetic Neuropathy - Pipeline by Neuralstem Inc, H1

Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt Ltd, H1

Diabetic Neuropathy - Pipeline by Omeros Corp, H1

Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1

Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1

Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H1

Diabetic Neuropathy - Dormant Projects, H1

Diabetic Neuropathy - Dormant Projects, H1 2017 (Contd..1), H1

Diabetic Neuropathy - Discontinued Products, H1

List of Figures:

Number of Products under Development for Diabetic Neuropathy, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achelios Therapeutics Inc
  • Angelini Group
  • Apollo Endosurgery Inc
  • Araim Pharmaceuticals Inc
  • Celgene Corp
  • Commence Bio Inc
  • Grunenthal GmbH
  • Kineta Inc
  • KPI Therapeutics Inc
  • Medifron DBT Co Ltd
  • Neuralstem Inc
  • NovaLead Pharma Pvt Ltd
  • Omeros Corp
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll